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Introduction: Activated platelets exert a proinflammatory action that can be largely ascribed to their ability to
interact with monocytes. However, the mechanisms that promote dynamic changes in monocyte subsets in
rheumatoid arthritis (RA) have not been clearly identified. The aim of this study was to determine whether platelet
activation and the consequent formation of monocyte-platelet aggregates (MPA) might induce a proinflammatory
phenotype in circulating monocytes in RA.
Methods: The surface phenotype of platelets and the frequencies of monocyte subpopulations in the peripheral
blood of RA patients were determined using flow cytometry. Platelets were sorted and co-cultured with monocytes.
In addition, monocyte activation was assessed by measuring the nuclear factor kappa B (NF-κB) pathway. The
disease activity was evaluated using the 28-joint disease activity score.
Results: Platelet activation, circulating intermediate monocytes (Mon2) and MPA formation were significantly
elevated in RA, especially in those with active disease status. Furthermore, Mon2 monocytes showed higher CD147
expression and responded to direct cell contact with activated platelets with higher cytokine production and matrix
metallopeptidase 9 (MMP-9) secretion, which increased the expression of CD147. After the addition of specific
antibodies for CD147, those effects were abolished. Furthermore, the NF-κB-driven inflammatory pathway may be
involved in this process.
Conclusions: These findings indicate an important role of platelet activation and the consequent formation of MPA
in the generation of the proinflammatory cytokine milieu and for the promotion and maintenance of the
pathogenically relevant Mon2 monocyte compartment in RA, which is likely to play an important role in the
pathogenesis of autoimmunity.Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease that is characterized by intense immune activation
within the synovial compartment of joints and a variety
of systemic manifestations. Monocytes and macrophages
are key players in RA pathogenesis that secrete proin-
flammatory cytokines, such as tumor necrosis factor
alpha (TNF-α) and interleukin 6 (IL-6) [1,2]. In the past,* Correspondence: zhuping@fmmu.edu.cn
†Equal contributors
1Department of Clinical Immunology, State Key Discipline of Cell Biology,
Xijing Hospital, Fourth Military Medical University, 127 West Changle Road,
Xi’an 710032, Shaanxi Province, PR China
Full list of author information is available at the end of the article
© 2014 Rong et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.monocytes were considered to be a homogeneous popula-
tion. Currently, at least three human monocyte popula-
tions can be defined by the expression of CD14, which is a
part of the lipopolysaccharide (LPS) receptor [3], and the
FcγIII receptor CD16 [4]. The CD14++CD16+ (‘intermedi-
ate’) monocyte subset remains the most poorly character-
ized because CD16+ monocytes had been analyzed as a
single population until they were shown to comprise two
subsets, the CD14++CD16+ cells and the CD14+CD16++
cells, and emerging functional and genetic evidence has
uncovered their distinct roles [5-7]. However, because
CD14++CD16+ and CD14+CD16++ monocytes overlap
when they are defined solely by the presence of CD14/16
expression, an unequivocal discrimination is necessary.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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CD14++CD16–CCR2+ (‘classical’ (Mon1)), CD14++CD
16 + CCR2+ (‘intermediate’ (Mon2)) and CD14 + CD
16++CCR2– (‘nonclassical’ (Mon3)), have been defined
[5-9]. Studies of autoimmune disorders that have re-
ported monocyte subset perturbation have mostly in-
volved RA [10-13] and Crohn’s disease (CD) [14-16].
Although the expansion of CD16+ monocytes in RA has
been clearly demonstrated in several studies [17,18], it
remained unclear until Rossol et al. reported a link be-
tween the increased frequency of the CD14brightCD16+
monocyte subpopulation in RA [10].
Recent studies have uncovered a novel platelet contri-
bution to disease pathophysiology in inflammatory arth-
ritis [19]. In humans, increased platelet activation is
evident in patients with RA compared with healthy con-
trol subjects. CD147, which is a platelet receptor that is
upregulated on activated platelets, is a critical mediator
of the positive regulators that are implicated in platelet
activation, and its binding to platelets fosters platelet de-
granulation. CD147 is a 57-kDa glycosylated transmem-
brane immunoglobulin that is also called extracellular
matrix metalloproteinase inducer (EMMPRIN). CD147
is capable of homotypic binding, which can lead to platelet
degranulation upon platelet binding and stimulation of
the nuclear factor kappa B (NF-κB) pathway in mono-
cytes, which lead in turn to the production of matrix me-
talloproteinase (MMP) and cytokines, specifically MMP-9,
TNF-α and IL-6 [20]. Although platelet CD147 has been
shown to be functional in vitro, little is known about
platelet CD147 expression in RA patients.
Monocyte-platelet aggregates (MPA) are heterotypic
complexes that are detectable in the peripheral blood
and form in response to platelet activation [21]. Accord-
ingly, the circulating MPA level increases in patients
who have a variety of autoimmune disorders [22]. How-
ever, the importance of monocyte-platelet interactions in
human inflammatory pathophysiology and the precise
mechanisms by which such interactions modulate mono-
cytic phenotype and function remain unclear. The aim of
this study was to investigate platelet activation, the dy-
namic changes in the monocyte subsets and the association
of MPA in RA patients. Second, we aimed to determine
the underlying mechanism by which monocyte-platelet




We enrolled 30 patients with active RA who satisfied the
American College of Rheumatology/European League
Against Rheumatism (ACR/EULAR) RA classification
criteria [23]. The mean age of these active RA patients
was 44 years (range 20 to 72), and the mean diseaseduration was 8 years. Patients had active disease that
was consistent with the criteria of activity: (1) ≥ six joints
were swollen; (2) ≥ six joints were tender; and (3) two of
the following three criteria were satisfied: (a) on the day
of the visit, morning stiffness lasted more than 45 minutes;
(b) erythrocyte sedimentation rate (ESR) ≥28 mm/h; and
(c) C-reactive protein (CRP) ≥20 mg/dl. All of the patients
in the study were either untreated or treated only with
nonsteroidal anti-inflammatory drugs. For all RA patients,
a composite 28-joint disease activity score (DAS-28) was
calculated to evaluate the disease status [24]. A DAS > 3.6
indicates an active disease status, and a DAS < 2.6 was
considered to reflect remission. Normal control peripheral
blood samples were taken from 10 healthy human donor
volunteers who had no significant age or sex differences
compared with the RA patients. The study was approved
by the Ethics Committee of the Fourth Military Medical
University. All of the patients and controls provided their
informed consent to participate in the study.
Reagents
Preconjugated fluorescent antibodies were from BD Bio-
sciences (San Jose, CA, USA) (CD14–phycoerythrin (PE),
P-selectin (CD62P)–PE, immunoglobulin G (IgG1)–PE,
CD16–PE-Cy5, CD40L–PE, CD42a–fluorescein isothio-
cyanate (FITC), PAC-1–FITC, CD147–FITC, TNF-α–
FITC, IL-6–FITC, CD61–PerCP, CCR2–Alexa Fluor and
BrdU Flow Kit). Anti-CD147 antibody was provided by
the Department of Cell Biology, Fourth Military Medical
University (Xi’an, China). An anti-IKK beta (IKKβ) anti-
body was also used (Abcam, Cambridge, UK).
Platelet isolation
Blood was diluted by the addition of Tyrode’s buffer at
pH 6.5 (134 mM NaCl, 2.9 mM KCl, 0.34 mM Na2HPO4,
12 mM NaHCO3, 20 mM HEPES, 1 mM MgCl2, 5 mM
glucose and 0.5 mg/ml bovine serum albumin (BSA)) and
centrifuged at 600 × g for 3 minutes. Platelet-rich plasma
(PRP) was further centrifuged for 2 minutes at 400 × g to
pellet the contaminating red blood cells (RBCs). This solu-
tion was thereafter centrifuged for 5 minutes at 1300 × g
to pellet the platelets. The platelets were resuspended in
Tyrode’s buffer at pH 7.4 and quantified cytofluorometri-
cally using anti-CD61 staining.
Cell isolation and culture
The fasting blood samples were collected in acid citrate
dextrose (ACD) anticoagulant tubes, and peripheral blood
mononuclear cells (PBMCs) were prepared using a Ficoll
density gradient for flow cytometric analysis [25]. Mono-
cytes were prepared using Ficoll density gradient centrifu-
gation and further isolated by positive selection using
antibody-coupled microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s
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alyzed using flow cytometry based on cell forward (FSC)
and side scatter (SSC), and these cells amounted to 96% of
the sample. The monocytes were suspended at a density
of 106 cells/ml in complete culture medium (RPMI 1640
supplemented with 100 U/ml penicillin and 100 μg/ml
streptomycin, 2 mM glutamine and 10% heat-inactivated
fetal calf serum; Gibco BRL/Life Technologies, Grand
Island, NY, USA). Aliquots of purified platelets were
added to the monocyte suspensions (1 ml final volume,
monocyte: platelet ratio 1:100 in experiments where
platelets were added) and incubated at 37°C in 5% CO2
for 48 hours.
Flow cytometry
The procedure for staining the cell surface proteins was
previously described [26]. Monocytes were first gated ac-
cording to their FSC and SSC dot plots, and then three-
color fluorescence was measured within the monocyte
gate. Monocytes were subclassified according to CD14
and CD16 expression. The CD14+CD16− (Mon1) cells
were defined as monocytes expressing CD14 but not
CD16. CD14+CD16+ monocytes were then further sub-
classified regarding CCR2 expression into CD14++CD16+
CCR2+ (Mon2) and CD14+CD16++CCR2− (Mon3). At
least 20,000 events in the monocyte gate were measured
per experiment. The results are presented as the per-
centages of positive cells. Circulating MPA was defined
by double positivity for CD14 and CD42a. Intracellular
staining of cytokines was performed using a BD Cytofix/
Cytoperm Fixation and Permeabilization kit (BD Biosci-
ences). Appropriately conjugated IgG antibodies were
used as isotype controls. After washing with phosphate-
buffered saline (PBS), the stained cells were subjected to
flow cytometry analysis using a fluorescence-activated
cell sorter (FACS) Calibur system and Cell Quest soft-
ware (BD Biosciences).
Monocyte cell function assays
Monocytes (1 × 106 cells/ml) from normal donors were
incubated with LPS, anti-CD147 monoclonal antibody
[27] or IKK inhibitor (Cell Signaling Technology, Danvers,
MA, USA), respectively, for 2 hours before co-culture or
indirect co-culture. Monocyte co-culture with purified
platelets (monocyte:platelet ratio 1:100 in experiments in
which platelets were added) was incubated at 37°C, 5%
CO2 for 48 hours. The indirect co-culture utilized Trans-
well culture chambers (Merck Millipore, Billerica, MA,
USA) containing polycarbonate filters (pore size, 0.4 μm),
allowing both cells to exchange soluble products through
a semipermeable membrane but preventing cellular
contact. Briefly, the monocytes (1 × 106 cells/ml) were
added to the upper chamber, while platelets (1 × 108
cells/ml) or medium alone was added to the lowercompartments. The proliferation of the monocyte sub-
sets was measured using BrdU Flow Kits according to
the manufacturer’s instructions.
Gelatin zymography
Serum-free conditioned medium samples were mixed with
sodium dodecyl sulfate (SDS) sample buffer and loaded
onto a 10% polyacrylamide gel containing 0.1% gelatin.
After electrophoresis, the gels were washed in 2.5% Triton
X-100 for 30 minutes and incubated for 16 hours in reac-
tion buffer. The gels were subsequently stained with 0.5%
Coomassie Blue (R-250) and destained to visualize the
zones of digestion as light areas against the darkly stained
background. The gels were then scanned and analyzed
using GeneSnap from SynGene Tools (Cambridge, UK).
Statistical analysis
The presented results were representative of a minimum
of three experiments and were expressed as the means ±
standard deviations (SDs). Statistical analysis was con-
ducted using Student’s t test or the Mann-Whitney U
test as appropriate, and multiple comparisons with a
single control were performed using analysis of variance
(ANOVA) with Dunnett’s t test modification. GraphPad
software (Cricket Software, Philadelphia, PA, USA) was
used for the above analysis, and P values less than 0.05
were considered significant.
Results
High expression of CD147, PAC-1, CD62P and CD40L on
platelets from RA patients
Flow cytometry showed the percentage of cells that stained
positive for CD147, PAC-1 and P-selectin (CD62P); the per-
centages of stained active (mean ± SD 47.63 ± 3.1, 41.73 ±
2.89 and 10.18 ± 1.15%, respectively) platelets and platelets
from patients with inactive RA (28.69 ± 1.42, 17.41 ± 1.63
and 3.99 ± 0.46%, respectively) were significantly higher
than those of healthy platelets (12.26 ± 0.83, 3.8 ± 0.44 and
0.39 ± 0.07%, respectively; P <0.05), especially in active RA
patients. The percentage of active RA platelets that stained
positive for CD40L (6.11 ± 0.44%) was higher than that of
healthy platelets (3.3 ± 0.56%; P <0.05), but the value for pa-
tients with inactive RA was not significantly different from
that of healthy platelets (3.66 ± 0.36%; P >0.05) (Figure 1).
Flow cytometry showed the percentages of cells that stained
positive for CD147, PAC-1, CD62P and CD40L in active
RA platelets, which were higher than those of inactive RA
platelets (P <0.01). Furthermore, the percentage of platelets
that were positive for CD147 expression was considerably
higher than those that were positive for PAC-1, CD62P and
CD40L expression in the overall population that was exam-
ined (Figure 1). Disease activity, which was evaluated using
DAS-28, was also significantly and positively correlated
with the expression of PAC-1, CD62P and CD147 (r = 0.50,
Figure 1 High expression of CD147, PAC-1, CD62P and CD40L
on platelets from RA patients. PAC-1, CD62P, CD40L and CD147
expression as percentages of positive platelets in healthy controls
(n = 10) and in patients with inactive RA (n = 10) and active RA
(n = 30). (Means ± SDs of the means, **P <0.001 and ***P <0.0001 vs.
corresponding controls). RA: rheumatoid arthritis; SDs: standard
deviations.
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of patients with active RA (Figure 2).
High percentages of Mon2 and Mon3 and the expression
of CD147 in peripheral blood from RA patients
Monocytes were subclassified into CD14++CD16−CCR2+
(Mon1), CD14++CD16+CCR2+ (Mon2) and CD14+CD16++
CCR2− (Mon3). The frequencies of Mon2 and Mon3
monocytes in peripheral blood samples from patients with
active RA (22.2 ± 1.45 and 17.17 ± 1.41%, respectively) or
patients with inactive RA (12.87 ± 1.27 and 13.33 ± 1.04%,
respectively) were higher than the percentages in the
healthy control group (7.26 ± 0.51 and 10.64 ± 0.56%, re-
spectively, P <0.05), especially for Mon2 (Figure 3A). A
detailed analysis of the demographic and clinical parame-
ters in the RA patients revealed no statistically significant
correlations for the expansion of Mon2 monocytes (data
not shown).
The expression of CD147 was increased in all three
subsets of monocytes from patients with RA, compared
with those of the healthy control subjects (Figure 3B).
The proportion of CD147 expression in the Mon1,Figure 2 DAS-28 was positively correlated with the expression levels
PAC-1 (r = 0.50, P = 0.0048), vs. CD62P (r = 0.57, P = 0.0009) and vs. CD147 (r
DAS-28: composite 28-joint disease activity score; P: platelet; RA: rheumatoiMon2 and Mon3 monocytes from patients with active
RA (45.15 ± 2.28, 24 ± 1.52 and 15.46 ± 0.911%, respect-
ively) or patients with inactive RA (34.47 ± 1.33, 12.24 ±
0.61, 12.19 ± 0.65%, respectively) was significantly increased
for all three subsets compared with those of the healthy
controls (29.47 ± 2.39, 6.74 ± 0.51 and 9.79 ± 0.46%, re-
spectively), except for the proportion of CD147 expression
on Mon1 monocytes in patients with inactive RA. The pro-
portion of CD147 expression on Mon2 monocytes in active
or patients with inactive RA compared with that of the
healthy controls was significantly (3.56-fold or 1.82-fold,
respectively) higher than the proportion of Mon1 (1.55-
fold or 1.17-fold, respectively) and Mon3 (1.58-fold or
1.25-fold, respectively) cells (Figure 3B).
High MPA levels and positive correlations with Mon2 and
with the expression of CD147 on platelets and Mon2
Patients with RA (active or inactive), compared with the
healthy controls, had significantly higher numbers of cir-
culating MPA (55.36 ± 2.53 and 37.32 ± 1.22, respectively
vs. 15.69 ± 3.33, mean ± SD; P <0.0001) (Figure 4A). More-
over, the proportions of Mon1, Mon2 and Mon3 mono-
cytes that aggregated with platelets in patients with active
RA (30.38 ± 1.65, 14.41 ± 1.28 and 9.23 ± 0.68%, respect-
ively) or patients with inactive RA (12 ± 0.72, 6.65 ± 0.33
and 5.87 ± 0.53%, respectively) compared with the healthy
controls (11.34 ± 0.82, 1.68 ± 0.39 and 2.67 ± 0.16%, re-
spectively) were all significantly increased (P <0.0001),
except for the proportion of Mon1 monocytes that
aggregated with platelets in patients with inactive RA
(Figure 4B). The proportion of Mon2 monocytes that
aggregated with platelets in patients with active or in-
active RA compared with healthy controls was signifi-
cantly (8.6-fold or 4-fold, respectively) higher than the
proportion of aggregated Mon1 (2.7-fold or 1.1-fold, re-
spectively) and Mon3 monocytes (3.5-fold or 2.2-fold,
respectively).
When examining the relationships between MPA
levels and other variables (the percentage of Mon2, theof PAC-1, CD62P and CD147 within active RA patients. DAS-28 vs.
= 0.63; P = 0.0002) expression as a percentage of positive platelets.
d arthritis.
Figure 3 High expression of Mon2, Mon3 and CD147 in the peripheral blood of RA patients. (A) The percentages of the monocyte
subsets and (B) the expression of CD147 in healthy controls (n = 10) and patients with inactive RA (n = 10) and patients with active RA (n = 30).
(Means ± SDs of the mean,*P <0.05, **P <0.001 and ***P <0.0001 vs. corresponding controls). Mon1: CD14++CD16−CCR2+; Mon2: CD14++CD16+
CCR2+; Mon3: CD14+CD16++CCR2−; RA: rheumatoid arthritis; SDs: standard deviations.
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CD147 on Mon2), a linear correlation was found between
the MPA levels and the percentage of Mon2 monocytes
(r = 0.66, P <0.0001) (Figure 4C), the expression of CD147
on platelets (r = 0.61, P = 0.0004) (Figure 4D) and the
expression of CD147 on Mon2 monocytes (r = 0.77,
P <0.0001) (Figure 4E). However, the levels of MPA cor-
related more closely with the percentage of expressed
CD147 on Mon2 monocytes than the percentage of
Mon2 monocytes that were present in individualFigure 4 High MPA levels and positive correlations with Mon2 and w
percentages of platelets that aggregated with monocytes and (B) the mon
(n = 10) and patients with active RA (n = 30). MPA levels (C) vs. the percent
platelets (r = 0.61, P = 0.0004) and (E) vs. the expression of CD147 on Mon2
active RA (means ± SDs of the mean, *P <0.05, **P <0.001 and ***P <0.0001
monocyte-platelet aggregates; Mon1: CD14++CD16−CCR2+; Mon2: CD14++Cpatients, whereas no such correlation was observed in
healthy control subjects. The levels of MPA did not cor-
relate with the percentages of Mon1 or Mon3 mono-
cytes (data not shown).
Platelet-monocyte interactions
To directly test whether intercellular contact is required
for differentiation of the monocyte subpopulations, mono-
cytes (1 × 106 cells/ml) from normal donors were incubated
with or indirectly co-cultured with RA platelets (1 × 108ith the expression of CD147 on platelets and Mon2. (A) The
ocyte subsets in healthy controls (n = 10), patients with inactive RA
age of Mon2 (r = 0.66, P <0.0001), (D) vs. the expression of CD147 on
monocytes (r = 0.77, P <0.0001) within the group of patients with
vs. corresponding controls). HD: healthy donors; P: platelet; MPA:
D16+CCR2+; Mon3: CD14+CD16++CCR2−; RA: rheumatoid arthritis.
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chambers, which allows both cells to exchange soluble
products through a semipermeable membrane but pre-
vents cellular contact. We found that the percentage of
Mon2 was higher when co-cultured with platelets from the
RA patient group (45 ± 3.6%, P <0.001) compared with the
no cellular contact (13.67 ± 2.33%, P <0.01) (Figure 5A),
CD147-blocking monoclonal antibody (mAb) (24.67 ±
2.03%, P <0.01) or control groups (7.63 ± 1.71%). The
percentage of Mon3 was also higher in the co-culture
with platelets from the RA patient group (32.67 ± 3.71%,
P <0.01) compared with the no cellular contact (14.00 ±
1.53%, P <0.01) and control groups (10.03 ± 1.78%), but
a significant (5.9-fold) increase in Mon2 was observed
(Figure 5A). Blockade of CD147 abrogated MPA formation
from monocytes in the presence of platelets (Figure 5B)
and also markedly reduced the percentage of Mon2
(Figure 5A). Following co-culturing with platelets, the
intracellular BrdU levels were significantly increased in
the Mon2 monocyte subsets (16.5 ± 1.5%, P <0.05) com-
pared with the control (5.5 ± 0.5%), CD147-blocking
mAb (8.5 ± 0.5%) or no cellular contact groups (7.5 ± 0.5%)
(Figure 5C).
CD147 on platelets stimulates cytokine expression and
MMP-9 production of monocytes via NF-κB activation
In this study, the intracellular TNF-α and IL-6 levels in
Mon2 monocytes were higher compared with the levels
in Mon1 and Mon3 monocytes. Following co-culturing
with RA platelets, the highest production levels of TNF-α
and IL-6 were detected in Mon2 monocytes (12 ±
1.16% and 12.63 ± 1.68%, respectively; P <0.01), whereas
their expression levels were significantly lower in the no
cellular contact (4.77 ± 0.43% and 4.97 ± 0.61%, respectively;
P <0.01), anti-CD147-blocking antibody (8.07 ± 0.72% and
8.00 ± 0.36%, respectively; P <0.05), IKK inhibitor (6.03 ±
0.61% and 6.33 ± 0.75%, respectively; P <0.05) and control
groups (2.83 ± 0.6% and 4.07 ± 0.58%, respectively; P <0.01)Figure 5 Platelet-monocyte interactions. Changes in the percentage of
(C) in monocytes contact co-cultured (M + P) or no cellular contact co-cult
of monocyte subsets and CD14+CD42a+ (MPA) cells, respectively, compare
are the effects of anti-CD147 blocking antibody (CD147mAb) or nonblockin
co-culture (n = 4 for each). (*P <0.05, **P <0.001 and ***P <0.0001 vs. corresp
RA: rheumatoid arthritis.(Figure 6A, B). Following co-culturing with platelets, the
intracellular IKKβ levels were significantly increased in
the Mon2 and Mon3 monocyte subsets (31 ± 3.61% and
17.33 ± 1.86%, respectively) compared with the control
(7.67 ± 1.2% and 5.33 ± 0.33%, respectively), anti-CD147-
blocking antibody (12.33 ± 1.2% and 8.3 ± 0.88%, re-
spectively) or no cellular contact groups (9.73 ± 0.93%
and 6.6 ± 0.7%, respectively) (P = 0.0036, P = 0.008 and
P = 0.0047, respectively, for Mon2; P = 0.0031, P = 0.0119
and P = 0.0057, respectively, for Mon3) (Figure 6C).
To investigate the capacity of CD147 on the platelet
surface to activate proteases, we co-incubated isolated
human platelets with isolated monocytes in which the
surface expression of CD147 had been reduced by pre-
treatment with CD147-blocking mAb. We found that
the interplay between freshly isolated RA platelets and
monocytes amplified MMP-9 activity (Figure 6D). In fact,
the CD147-blocking mAb-induced inhibition of CD147
expression on monocytes reduced this effect, suggesting
that platelet-monocyte interactions contribute to MMP-9
secretion. To test the hypothesis that platelet-monocyte
interactions evoke protease stimulation by activating NF-
κB, we pretreated human isolated monocytes with an IKK
inhibitor and then incubated them with platelets. As
depicted in Figure 6C, co-culturing with platelets led to
the activation of MMP-9, which was hindered by inhib-
ition of the IKK complex. Stimulation with bacterial LPS
was used as a positive control. Together, these results indi-
cate that CD147 stimulates MMPs and activates broader
inflammatory processes via NF-κB translocation with the
prevailing proinflammatory responses.
Discussion
RA is a chronic, autoimmune, inflammatory disease that
primarily affects synovial joints, and its cause remains
obscure. The aim of this study was to determine if plate-
lets induced the proinflammatory phenotype of monocytes
in RA. Elevated CD14highCD16+ monocyte frequenciesmonocyte subsets (A), MPA (B) and intracellular expression of BrdU
ured with platelets from RA patients (M/P), expressed as percentages
d to monocytes cultured in medium alone (M) after 48 h. Also shown
g control antibody (control mAb) added to monocyte-platelet
onding controls). MPA: monocyte-platelet aggregates; P: platelet;
Figure 6 CD147 on platelets stimulates cytokine expression and MMP-9 production of monocytes by NF-κB activation. Isolated human
monocytes were pretreated with medium (M), with anti-CD147-blocking antibody (CD147mAb), with IKK inhibitor, with nonblocking control
antibody (control mAb) and with lipopolysaccharide (LPS, positive control) for 24 hours. Thereafter, monocytes were washed and contact
co-cultured (M + P) or no cellular contact co-cultured (M/P) with freshly isolated platelets from RA patients for an additional 24 hours. Subsequently,
intracellular expression of TNF-α (A), IL-6 (B) and IKKβ (C) in monocyte subsets and MMP-9 activity (D) were determined (mean ± standard
error of the mean, P >0.05, *P <0.05, **P <0.001 and ***P <0.0001 vs. corresponding controls). IL-6: interleukin 6; LPS: lipopolysaccharide; mAb:
monoclonal antibody; MMP: matrix metalloproteinases; MPA: monocyte-platelet aggregates; NF-κB: nuclear factor kappa B; RA: rheumatoid
arthritis; TNF-α: tumor necrosis factor alpha.
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cause the CD14++CD16+ and CD14+CD16++ subsets over-
lap when they are defined solely by the presence of CD14/
16 expression, an unequivocal discrimination is necessary.
In keeping with recent data and statements of the consen-
sus on the nomenclature of monocyte subsets, we ob-
served that two phenotypically and functionally distinct
CD16+ subsets can be reliably discriminated based upon
their expression of CCR2. CD14++CD16+CCR2+ (Mon2)
cells are a distinct population of monocytes that can be
distinguished from the classic CD14++CD16−CCR2+
(Mon1) and nonclassical CD14+CD16++CCR2− (Mon3)
monocyte populations. Our study showed high frequen-
cies of Mon2 monocytes in peripheral blood samples
from active RA patients, which was consistent with the
results of other studies that linked Mon2 monocytes to
other inflammatory diseases [28], and suggests a proin-
flammatory role for these cells. Moreover, the increased
frequency of Mon2 monocytes might be an indirect con-
sequence of fewer circulating Mon1 monocytes, which are
considered less mature than Mon2 monocytes, indicating
that circulating monocytes in RA are globally more ma-
ture than in healthy donors, or because Mon1 monocytes
infiltrated the inflamed joints and thus are less repre-
sented in the circulation. However, the mechanisms of thehigh frequencies of Mon2 monocytes in RA patients are
unknown and deserve further exploration. A previous
study showed that CD147 is preferentially expressed on
activated inflammatory cells, such as monocytes or foam
cells. We hypothesized that the increased surface expres-
sion of CD147 on Mon2 monocytes is a further indication
for their involvement in inflammatory immune responses.
The platelet expression of CD147 has been reported
[21] and may have various biological functions, including
the induction of MMP expression. We report the high
expression of CD147 on circulating platelets in RA
patients. We further show marked associations among
platelet CD147 surface expression, monocyte (and their
individual subsets) CD147 expression, inflammatory
markers and traditional markers of platelet activation,
such as CD62P and PAC-1. Furthermore, with the use of
whole-blood flow cytometry to minimize artifactual acti-
vation due to handling, the percentage of platelets that
were positive for CD147 was much greater than the per-
centage that was positive for CD62P or PAC-1, which sug-
gests that circulating platelets may express CD147 in a
more constitutive manner than their expression of CD62P
or PAC-1. Platelet CD147 may be a unique marker of the
effect of disease activity on platelet activation status.
Moreover, we found a positive correlation between CD147
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which is in agreement with our finding of traditional
markers of platelet activation in active RA patients. In
addition, CD147 is capable of homotypic binding, which
can lead to platelet degranulation upon platelet binding
[21]. These findings suggest that CD147 expression on
platelets may be of pathogenic relevance to RA. Our
findings also indicate that the high expression of CD147
on platelets that correlated with disease activity parame-
ters might reflect the degree of systemic inflammation
and could be a potential biomarker for disease activity
in RA patients.
The formation of MPA has been reported to be in-
creased in patients with RA. In our study, a linear correl-
ation was found between MPA levels and the expression
of CD147 on platelets. In the present study, we demon-
strated that the numbers of Mon2 monocytes increased
during the active phase of RA in the presence of activated
platelets and the consequent MPA formation, and that
anti-CD147 blocking antibody group, which we found to
abrogate MPA formation and phenotypic shifts, appears
to be induced by contact co-culturing of platelets and
monocytes. Although other groups have reported that
platelets can alter monocytic CD16 expression [29], this
observation has been interpreted as an effect on the ter-
minal monocytic maturation toward macrophages. Our
in vitro results, together with our co-culture model data,
demonstrate that physical contact of monocytes with
platelets is critical in this process, most likely by CD147/
CD147 interactions between these cells, triggering a
change in the circulating monocyte phenotype rather than
a terminal differentiation event. Furthermore, our study
found a linear correlation among MPA levels, the percent-
age of Mon2 monocytes and the expression of CD147 on
Mon2, which suggests that platelets are functionally linked
to the observed expansion of the Mon2 subpopulation
in RA. BrdU experiments confirmed these results and
verified that CD147-upregulated platelets may act as
amplifiers of the pathogenetic cascade by directly con-
tacting monocytes.
In this study, we found that the contact co-culturing
of platelets and monocytes resulted in an increase in the
percentage of Mon2 monocytes but no difference in the
noncontact co-culture group or on the effect of Mon2
and Mon3 monocytes that was abrogated by CD147
mAb in the CD147-blocking mAb group. In addition,
Mon2 monocytes have more elevated intracytoplasmic
levels of proinflammatory cytokines (including IL-6 and
TNF-α) than Mon1 and Mon3 monocytes, which is in
keeping with their ability to produce a modified proin-
flammatory response. The correlation between platelets
and monocytes may be explained by the concurrent acti-
vation of CD147 on the platelet and monocyte popula-
tions, especially Mon2 monocytes, by common agonists.For example, homotypic binding to monocyte CD147 in-
duces the production of IL-6 and TNF-α [21]. Some of
these factors are likely to cause platelet activation [30-32]
and would be expected to correlate with RA disease activ-
ity, which we show here in accordance with platelet CD147
expression. Furthermore, Zhou et al. demonstrated that
CD147 expression is upregulated during the differentiation
of monocytes into macrophages and that this upregulation
induces the secretion and activation of MMP-2 and MMP-
9 and enhances the invasive ability of monocytes [33]. This
finding is in agreement with our finding that monocyte-
derived MMP-9 activity was induced more in contact
co-cultures with RA platelets with a high expression of
CD147. In accordance with Galt et al. [27], the CD147-
blocking mAb reduced this effect, which suggested that
CD147-CD147 binding contributes to MMP-9 secretion
during platelet-monocyte interactions. Together, these re-
sults indicate that CD147 on the platelet surface interacts
with CD147 on monocytes to stimulate MMP-9 activity
and that CD147 may represent a novel target to diminish
the burden of protease activity and inflammation in RA.
Although CD147 plays an important role in the inter-
action between Mon2 monocytes and platelets, the path-
ways by which CD147 mediates intracellular activation
are not well understood. We showed that CD147 acti-
vates NF-κB, which, in turn, leads to the production of
MMP-9 and proinflammatory cytokines (including IL-6
and TNF-α), which can be reduced by adding either
CD147 mAb or NF-κB inhibitors in vitro. These data sup-
port our previous observation of the increased surface ex-
pression of CD147 on circulating monocytes in RA [34],
which is a condition that is associated with increased
plasma levels of IL-6 and TNF-α [35-37]. Moreover, al-
though the NF-κB pathway was activated in the Mon2 and
Mon3 monocyte subsets (that is, an increase in intracellu-
lar IKKβ levels) following contact co-culture of platelets
and monocytes, the highest value of this key transcriptional
factor was observed in Mon2, which was due to their
prominent function in the promotion and generation of
the proinflammatory cytokine milieu. To the best of our
knowledge, a regulatory function of CD147 in monocyte
subsets and the production of inflammatory cytokines have
not been described for RA. Thus, these data support the
concept that CD147-mediated cellular interaction between
CD147 on the cell surface regulates broad, NF-κB-related
Mon2 monocyte activities rather than pure MMP activity.
Furthermore, CD147 may play an important role in sys-
temic inflammation and thus represents a potential future
therapeutic anti-inflammatory target.
Conclusions
In summary, the findings of this study extend the role of
CD147 expression on platelets in RA. Moreover, these
findings indicate an important role of Mon2 monocytes
Rong et al. Arthritis Research & Therapy  (2014) 16:478 Page 9 of 10in the promotion and generation of the proinflammatory
cytokine milieu, which is strongly related to and may be
driven by the extent of platelet activation. Our findings
shed new light on the relevance of platelet-monocyte in-
teractions in the pathophysiology of RA, and CD147
may play an important role in this process via the NF-κB
pathway. The inhibition of CD147 may be a promising
target for novel therapeutic strategies in RA patients.
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